Patient Access to Medicines in Greece


An Industry perspective

Nikos Kefalas SfEE Vice President Managing Director, Janssen Pharmaceutical Greece

TACD Conference on A2M – Athens, May 31st 2013


Public outpatient pharmaceutical expenditure: net saving of €2.7 bil. in 4 years (2013 vs 2009)

Reached MoU targets, (clawback) <€40 mil. in 2012




Source: IOBE / SFEE, Facts & Figures 2012

Net Public Pharmaceutical Expenditure per capita in Greece 2013: average of EU vs Greece ($\in 2.44$ bil.): +50%! 2014: average EU vs Greece ($\in 2.1$ bil.): +80%!



The main consequence:

Significant difficulties to get access in medicines in private & public pharmacies and Hospitals, especially for severe diseases



Main aspects of Patient access issues

- Difficulties to pay for their contribution in therapies
- Bureaucracy, delays and obstacles to get medicines from public hospitals & pharmacies (e.g. L.3816 medicines)
- Market shortages / supply issues
- No pricing & reimbursement approval for new innovative medicines for almost 2,5 years



The main causes

- Harsh economic and social situation Increasing number of people without insurance coverage/ unemployed
- Issues in re-pricing process
- Increase in patient co-payment
- Accumulated arrears to healthcare providers/ significant delays in payments
- Limited budgets of public hospitals non supply of severe disease medicines

SfEE mission: Patient access to new and existing therapies – What are our proposals ?

Price approval for all new medicines (prototype/Gx), pending approval for ~2,5 years - Gradual reimbursement by Social Security Funds

Reform of the pricing system/methodology, to ensure simplicity and avoid market shortages and international reference price issues (Average of 3 EU lowest prices for all prototype products is the solution)

Continuous flow of payments from public institutions to healthcare providers/ Payment of all accumulated arrears

Simplification of positive list & reimbursement mechanism and restoration of rationale patient co-payment levels, especially for certain severe disease areas

> Ensure the appropriate funding of hospitals/EOPYY, to ensure the smooth supply of medicines to patients Re-adjust MoU goals for pharmaceutical spending

Thank you

Discussion

